Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$46.39 USD

46.39
1,734,859

-1.14 (-2.40%)

Updated Jun 14, 2024 12:17 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate

by Zacks Equity Research

AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.

Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion

by Zacks Equity Research

The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

by Zacks Equity Research

Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.

TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

by Zacks Equity Research

TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

GSK Stock Dips on Delaware Court Ruling for Zantac Litigation

by Zacks Equity Research

GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.

FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD

by Zacks Equity Research

Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

by Kinjel Shah

J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.

J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate

by Zacks Equity Research

J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.

Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

by Zacks Equity Research

AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.

Sanofi (SNY) Signs Deal for AI-Powered Drug Development

by Zacks Equity Research

Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.

Why Novavax (NVAX) Stock Price Appreciated 14% on Monday

by Zacks Equity Research

Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

by Zacks Equity Research

Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Oracle, Bank of America & McDonald's

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Bank of America Corporation (BAC) and McDonald's Corporation (MCD), as well as two micro-cap stocks Miller Industries, Inc. (MLR) and Via Renewables, Inc. (VIA).

Ekta Bagri headshot

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

by Ekta Bagri

Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.

Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal

by Zacks Equity Research

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.

Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

by Zacks Equity Research

Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.

Company News For May 13, 2024

by Zacks Equity Research

Companies In The Article Are:NVAX, SNY, MRNA, G and IAG.

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

by Zacks Equity Research

Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

by Zacks Equity Research

An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates

by Kinjel Shah

Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.

AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

by Zacks Equity Research

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.